Evidence-Based Medicine Guidelines
Primary hyperaldosteronism (PHA)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Primary Hyperaldosteronism (PHA)." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/452591/all/_________Primary_hyperaldosteronism__PHA_______.
Primary hyperaldosteronism (PHA). Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/452591/all/_________Primary_hyperaldosteronism__PHA_______. Accessed November 4, 2025.
Primary hyperaldosteronism (PHA). (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/452591/all/_________Primary_hyperaldosteronism__PHA_______
Primary Hyperaldosteronism (PHA) [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 November 04]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/452591/all/_________Primary_hyperaldosteronism__PHA_______.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Primary hyperaldosteronism (PHA)
ID - 452591
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452591/all/_________Primary_hyperaldosteronism__PHA_______
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
